VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Theravance Biopharma (TBPH – Research Report) today and set a price target ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – ...

Ken's career includes key leadership roles in organizations such as the Ontario Government, Victoria University (Toronto), Brock University, Cystic Fibrosis Canada, and Vertex Pharmaceuticals. His ...

"Developer confidence in the market has diminished significantly, resulting in the sale of underperforming new developments," ...

DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...